TCL Archive FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says. January 14, 2005
TCL Archive In Brief: NCI Holds Paylines To 160, 165 for Now While Anticipating Another OMB Rescission Request November 14, 1986
TCL Archive NCI Bypass Budget Request For FY 1982Seeks $1.192 Billion; Would Fund 40% Of Competing R01s May 23, 1980
TCL Archive NCIs FY95 Bypass To Justify $3.47 Billion, includes $490 million For Breast Cancer Research May 14, 1993